Two stories landed this week that together explain exactly where cannabis stands.
In the first, researchers found that when a recreational dispensary opens, neighboring businesses see roughly 7.47% more revenue. More customers, more transactions, more money flowing through the block. Not bad for an industry that spent years being treated as a threat to neighborhood commerce.
In the second, a cannabis cultivator won a $31.8 million jury verdict in a commercial dispute, and a federal appeals court threw it out because the underlying agreement involved marijuana.
Sit with that contradiction for a second. Cannabis retail can measurably lift the businesses around it, and cannabis businesses still can’t count on a signed contract holding up in federal court.
That tension runs through everything this week. Nebraska voters approved medical marijuana nearly two years ago and patients still can’t reliably get it. Massachusetts voters look ready to defend their market from repeal. Trump’s cannabis approval among consumers has collapsed from 73% to 29% in two quarters. Hemp companies are literally mailing THC six-packs to Congress ahead of a December deadline. The industry has millions of consumers, billions in transactions, professional management, and established supply chains, and it still doesn’t operate under the same legal assumptions as a hardware store. Let me walk you through it.
Nebraska approved medical marijuana two years ago. Patients are still waiting.
Nebraska voters passed medical-marijuana measures in November 2024, and implementation remains deeply contested. Now it’s a campaign issue. Democratic gubernatorial candidate Lynne Walz says she’d issue an executive order on day one to accelerate patient access, arguing Governor Jim Pillen’s administration has failed to implement what voters approved, and she’s suggested replacing members of the Nebraska Medical Cannabis Commission if delays continue.
Big promise, and the underlying question goes well past party politics: what happens when voters approve legalization and the regulatory system doesn’t deliver?
A ballot measure is a political milestone. An operating dispensary is a practical one. A reliable medical market is something else entirely, and Nebraska has only cleared the first.
Building a functioning market takes rules, licenses, facilities meeting operating requirements, and lawful paths for patients to actually obtain product. When those steps get prolonged or politically contested, legalization exists on paper without functioning in practice. Walz’s proposed order is meant to speed that up, though executive authority has limits, since a governor can’t override every statutory requirement or rewrite the licensing framework alone. The practical question is what an order could actually accomplish versus what still needs legislative or regulatory approval. That matters for patients, who mostly just want to know whether they can legally buy something. It matters for businesses too, because a prospective dispensary may be willing to invest but needs to know how many operators get authorized, what they can sell, what compliance looks like, and how fast revenue starts. Delay has a price in accumulating legal fees, expiring real estate options, and impatient investors, and those costs can wreck the economics of an otherwise promising market. Worth noting for anyone watching: a favorable election doesn’t guarantee market access either, since licensing, construction, staffing, and supply chains all take time.
The bottom line: Nebraska turned implementation into an election issue. The question isn’t whether voters approved legalization, it’s whether the state can convert that into actual patient access.
Dispensaries lift the businesses around them by about 7.47%.
This is the most commercially interesting story of the week. Researchers from the City University of New York, Northern Illinois University, and the University of Miami examined Illinois cannabis-market development between 2021 and 2024, combining dispensary-opening data with credit and debit card transaction data and neighborhood characteristics. After recreational dispensaries opened, nearby establishments saw roughly 6.82% more customers, 8.01% more transactions, and 7.47% more revenue.
Those are meaningful numbers for businesses running on thin margins, and they cut directly against the assumption that cannabis retail harms surrounding commercial districts. The researchers found most of the benefit came from additional foot traffic rather than higher spending per customer, which is an important distinction. Neighbors weren’t making more per transaction, they were getting more people through the door.
Retail landlords already evaluate tenants partly on their ability to generate foot traffic. Grocery stores and fitness centers anchor centers for exactly that reason. The question this study raises is whether a dispensary can play the same role.
The limitations are real, since this reflects Illinois during a specific period and shouldn’t be assumed to apply to every city or shopping center, with local demographics, parking, walkability, and competition all affecting outcomes at any individual location, and the analysis doesn’t establish that every nearby business benefits equally. But for anyone evaluating cannabis-related commercial real estate, the findings matter, because lenders and property owners have historically treated cannabis tenants primarily as regulatory risk. That risk hasn’t disappeared. The potential upside now deserves weighing alongside it, since a dispensary with strong sales and reliable management may support surrounding activity, increase occupancy demand, and strengthen a retail corridor. For municipalities, it should inform zoning debates, because restrictions may be justified by specific land-use or public-health concerns, but broad assumptions about negative economic effects should be tested against evidence. And for operators, there’s a straightforward business-development play here in building relationships with neighboring merchants, joining local business associations, and demonstrating contribution to the district.
🎯 The bottom line: Cannabis retail may generate real positive spillovers beyond its own sales. Watch whether other states replicate it and whether municipalities start factoring it into zoning.
Massachusetts voters look ready to defend their market.
Two new polls suggest Massachusetts voters want to keep the recreational market they built. A UMass Amherst and WCVB-TV survey found roughly 61% opposition to Question 8, the November measure rolling back commercial legalization, while a Suffolk University and Boston Globe poll found about 71% opposition. Substantial margins, though the election hasn’t happened.
The measure would eliminate the framework supporting recreational sales and home cultivation while leaving possession legal and the medical program intact, producing the odd result where adults can possess marijuana with no regulated retail market supplying it. The stakes are enormous, since Massachusetts has recorded more than $10 billion in cumulative adult-use purchases since 2018, supporting retailers, cultivators, manufacturers, employees, service providers, and tax revenue.
Picture a dispensary on a long-term lease with millions in improvements, security systems, equipment, inventory, financing obligations, and dozens of employees. A framework change doesn’t just hurt the owner. It hits the landlord, the lender, the vendors, and the staff.
Which raises the question that extends well past this state: how much confidence can investors place in a state-licensed market when the commercial framework stays vulnerable to repeal? Cannabis already carries substantial federal uncertainty, and adding state-level reversal risk makes long-term planning considerably harder. Supporters of Question 8 raise public-health concerns including impaired driving, which deserve real consideration since cannabis can impair driving and legalization requires enforcement and education. Opponents counter that eliminating regulated sales pushes consumers toward unlicensed suppliers with no oversight of testing, labeling, or age verification. The question isn’t whether consumption carries risk, it does, it’s whether that risk is better managed inside a regulated market or outside one. The polling reassures operators without justifying complacency, because polls are estimates, turnout matters, and campaigns move voters.
🎯 The bottom line: Voters appear inclined to preserve the market, but November decides it. Political risk belongs in cannabis underwriting even when a market looks mature.
Trump’s cannabis approval fell 44 points in two quarters.
A new quarterly NuggMD and Marijuana Moment survey found 29% of respondents approve of the administration’s cannabis-policy actions, down from 48% last quarter and 73% the quarter before. That’s a 44-point slide from the peak. The survey covered 654 cannabis consumers in legal-market states, interviewed October 8 through 15, with 20% disapproving and a majority at 51% reporting neutral views or no opinion.
That last number matters for reading this correctly. The results don’t show most consumers opposing the administration, they show positive sentiment collapsing into neutrality. And the sample isn’t representative of all American voters, it’s specifically consumers in legal states.
Still, the trend is clear. Early enthusiasm followed federal action on Schedule III classification, but broader rescheduling sits in a separate administrative proceeding that has hit delays and procedural challenges, with opponents seeking additional review including consideration of a GAO report on federal drug-scheduling procedures.
Schedule III has long been associated with better tax treatment, research access, and a friendlier operating environment. Anticipated benefits are not the same as benefits currently available to your business, and that distinction is where financial plans go wrong.
Picture a company forecasting major tax savings, management planning expansion, investors raising their valuation, and a lender asked to underwrite debt against projected after-tax improvements. If the relevant changes haven’t taken effect for that company’s activities, the savings are speculative. A prudent lender separates current cash flow from prospective regulatory upside, and the same logic applies to valuation, where a company shouldn’t get full credit for earnings dependent on unresolved administrative decisions. The survey also asked about broader legalization, with 47% saying it would increase their support for the administration and 52% saying their support wouldn’t change, which suggests more reform could move some consumers without guaranteeing a broad shift.
🎯 The bottom line: Announcements create optimism, implementation determines whether it lasts. The industry has visibly shifted its attention from what Washington says to what actually changes.
A hemp company wants you to mail Congress a six-pack.
With the federal deadline closing in, Herb Light launched a campaign called Cheers Against Prohibition, letting customers who buy a 12-pack purchase an additional six-pack intended for their congressional lawmakers, with the company coordinating delivery and including a letter supporting legislation that preserves a regulated hemp THC market.
Clever publicity, serious problem underneath. Many hemp-derived THC products face significant restrictions starting December 11, when the revised federal hemp definition means finished products containing more than 0.4 milligrams of total THC per container generally stop qualifying as hemp, with certain synthetic cannabinoids facing an earlier deadline.
Plenty of THC drinks are formulated at 5 or 10 milligrams. Reformulating below 0.4 isn’t a tweak, it’s a different product, and consumers may simply decide it no longer does what they bought it for.
That’s an expensive problem for manufacturers who’ve invested in formulations, packaging, production equipment, brand development, and distribution relationships. Herb Light is better positioned than most, since its beverages contain roughly 1 milligram and it says it could potentially reformulate under the threshold, though reformulation guarantees nothing, because the product still has to appeal to consumers, retailers still need confidence it moves, and the economics still have to support manufacturing and distribution. The campaign also surfaces the bigger policy question of whether low-dose THC beverages belong in conventional adult retail or should be restricted to cannabis dispensaries, and both approaches have merit, since conventional retail improves access and creates opportunity while requiring real age verification, testing, labeling, and training, and dispensary-only distribution offers stronger existing oversight while limiting access and raising costs. The ideal framework accounts for actual product risk, because a low-dose beverage isn’t a highly concentrated edible even though both need consumer protections. One practical wrinkle: congressional gift rules may limit whether these deliveries can even be accepted.
The bottom line: The December deadline is already shaping product development, inventory planning, and distribution decisions. The advocacy is loud because the financial decisions are immediate.
The $31.8 million question: are cannabis contracts enforceable?
This is the most important story here for operators, lenders, and investors. A federal appeals court overturned a $31.8 million jury award involving a Michigan cannabis cultivator and subsidiaries of Curaleaf. The dispute concerned a marijuana purchase agreement, with Hello Farms alleging the buyers failed to meet their contractual obligations, and a jury awarding substantial damages. The Sixth Circuit overturned it because the agreement involved activities prohibited under federal marijuana law. NORML is now urging the court to reconsider, arguing that refusing to enforce cannabis contracts undermines accountability in state-regulated markets.
Contracts are the foundation of commercial relationships. Businesses rely on purchase agreements, suppliers on payment commitments, investors on representations and covenants, and lenders on enforceable obligations when evaluating collateral and repayment capacity.
A cultivator has a purchase agreement with a major retailer. The lender treats it as evidence of future revenue. Then the buyer doesn’t perform. What remedy exists? Can the lender rely on that receivable? Those aren’t theoretical questions, they drive underwriting, loan structure, collateral valuation, and pricing.
The ruling doesn’t make every cannabis contract unenforceable, since outcomes depend on jurisdiction, contract terms, governing law, and the relief sought, and state courts may handle these differently than federal courts. Nobody should generalize this into a nationwide rule. But it illustrates a serious risk, where a business can satisfy every state licensing requirement and still hit a federal wall in an ordinary commercial dispute. NORML’s argument draws a useful distinction, that courts should consider whether a particular remedy can be provided without requiring unlawful conduct, since enforcing a damages award isn’t the same as ordering a party to engage in prohibited activity. Their broader point is that a categorical refusal to enforce weakens the accountability regulated markets are supposed to deliver, which reaches past commercial fairness, because purchase agreements often contain product-quality requirements, testing obligations, delivery standards, and defect provisions. If those can’t be enforced, consumers feel it too. For lenders, the practical takeaway is that a signed purchase agreement isn’t automatically reliable collateral, and its enforceability needs evaluating, same as acquisition agreements, leases, and distribution contracts.
The bottom line: A functioning cannabis economy needs more than legal sales. It needs contracts that mean something when someone breaches them.
Veterans overwhelmingly want cannabis research. Most aren’t telling their doctors.
A new Iraq and Afghanistan Veterans of America survey of 470 members found 87% supporting medical marijuana legalization, 61% supporting recreational legalization, 91% supporting research into cannabis’s medical potential, and 88% supporting VA-conducted research. Strong numbers, though they reflect respondents from one organization and shouldn’t be read as representative of all U.S. veterans.
The more interesting finding is the gap. Seventy percent said they’d feel comfortable discussing medical cannabis with their primary care physician. Only 29% have actually had that conversation.
Clinicians need accurate information about what their patients use, since cannabis can affect impairment, sleep, and mood and interact with medications. When patients stay quiet, doctors make decisions with missing information, and that gets riskier when multiple conditions and prescriptions are involved.
Veterans may be interested in cannabis for chronic pain, sleep, anxiety, or medication interactions, but interest doesn’t establish that a specific product works for a specific condition, which is exactly why research matters. The organization’s recommendations emphasize research and better access to medical information, which is the right direction, since the goal should be identifying where cannabis provides benefit, where risks outweigh it, and where the evidence simply isn’t there yet. Research shouldn’t be designed to validate a political position, it should answer clinical questions. For the industry, this creates opportunity and responsibility at once, because companies should support credible research while avoiding marketing products as proven treatments for PTSD or chronic pain without appropriate evidence. Personal experience identifies questions worth studying and cannot replace controlled trials. The same discipline applies to investment, where a medical-cannabis company’s valuation should reflect the strength of its evidence, regulatory pathway, and commercial prospects rather than the number of consumers expressing interest.
The bottom line: Surveyed veterans strongly support access and research. The next step is better evidence and making it easier to have the conversation honestly.
MPP: the fix for unfair hemp rules isn’t more prohibition.
The industry’s internal fight over hemp THC keeps escalating, and the Marijuana Policy Project is defending its position. In a new opinion piece, executive director Adam Smith argues the differences between hemp and marijuana regulation are real but that returning hemp THC products to broad prohibition is the wrong answer. He’s responding to criticism from Chris Lindsey, a former MPP staffer now with a cannabis and hemp industry association, who has argued intoxicating hemp products compete unfairly with licensed marijuana businesses.
Smith concedes the problem is genuine. State-licensed operators face licensing fees, security obligations, inventory tracking, testing, high taxes, and limited banking access, while hemp businesses developed under a different framework where some products move through conventional retail, some companies use ordinary payment services, and some benefit from tax treatment marijuana operators can’t get. A dispensary selling THC products can face substantially higher operating costs than a hemp retailer selling something comparable, and licensed operators are right to question whether that’s fair.
His argument is that the answer is consistent regulation, not prohibition. A coherent framework could set standards based on potency, formulation, and consumer risk, with real testing, accurate THC labeling, mandatory age verification, and retailer accountability.
That doesn’t mean every cannabinoid product needs identical distribution restrictions, since a low-dose beverage may warrant a different approach than a highly concentrated edible, and the challenge is writing standards that protect consumers without creating arbitrary distinctions. Smith also flags what happens if you restrict legal hemp access in states with no conventional marijuana market, because consumers buying hemp THC today won’t simply stop, they’ll go to unregulated sources, travel to neighboring states, or buy illicitly, which defeats the consumer-protection goal. Preserving hemp access without adequate regulation carries its own risks though, since potency varies, labeling can be inaccurate, and certain manufacturing methods need evaluation for contaminants. So the debate shouldn’t be framed as unrestricted retail versus prohibition, because intermediate approaches exist. For businesses, the immediate concern is December, determining which products face restrictions, whether reformulation is feasible, and how changes hit inventory and revenue. For lenders, this is concentration risk in plain sight, since a borrower leaning heavily on hemp THC sales has regulatory exposure that converts directly into repayment risk.
The bottom line: The real question is whether the industry wants a unified cannabinoid marketplace or competing regulatory systems. Eliminating one category of business doesn’t answer it.
Tuesday closing
This week’s stories say something worth naming directly. Cannabis has moved past the legalization debate, and the problems that replaced it are harder.
Start with the dispensary study, because it’s genuinely encouraging. Opening a recreational retailer can increase economic activity at nearby businesses, which suggests cannabis retail contributes to local commercial development rather than displacing it. Landlords, municipalities, and economic-development groups should pay attention to that. But it begs an obvious question: if cannabis businesses generate measurable economic benefit, why do they still face such unusual commercial obstacles? The $31.8 million contract dispute is the answer. Federal prohibition still breaks ordinary business relationships, and a state-licensed company can sign an agreement and later discover real uncertainty about whether it’s enforceable. For an industry chasing conventional financing, that’s disqualifying. Lenders need reliable contracts, investors need predictable remedies, operators need partners who can be held accountable, and without that foundation capital gets more expensive and businesses get harder to finance.
Nebraska shows a different failure, where voters approved medical marijuana and practical implementation stalled, leaving patients waiting, businesses uncertain, and investors staring at a market they can’t enter. Massachusetts shows the inverse, an established industry facing a ballot measure that could rewrite its market, where the polling is reassuring but the existence of the question proves regulatory risk doesn’t vanish once a market opens. Federal rescheduling adds the third variation, where consumer enthusiasm is falling not because support for reform disappeared but because people are waiting for implementation to actually arrive. Businesses are doing the same math, since a favorable announcement doesn’t improve cash flow, guarantee banking, or remove obstacles. And hemp faces the most immediate version of all of it, with December restrictions threatening established products and distribution, some licensed operators seeing necessary fairness and others seeing renewed prohibition, and both sides raising points that deserve a hearing.
What ties all eight together is that cannabis is no longer fighting for permission to exist. It’s fighting for the institutional foundations that let a legitimate industry function: enforceable contracts, reliable banking, reasonable tax treatment, consistent regulation, credible research, and stable commercial expectations. None of that makes for exciting headlines, and all of it determines who survives. A license isn’t profitability. A political promise isn’t cash flow. A large addressable market isn’t commercial success. The next generation of winners will need reliable financial reporting, experienced management, appropriate capitalization, documented compliance, and realistic growth plans, while lenders weigh regulatory exposure alongside ordinary credit fundamentals and policymakers figure out how to protect consumers without destroying legitimate businesses. Legalization created the opportunity. Regulation sets the operating environment. Contracts establish accountability. Capital supports growth. Execution decides who’s still here.
That’s what this newsletter is for.
What’s the biggest regulatory challenge your operation is facing right now? Hit reply, I read every response and it shapes what I cover next week.
If this was useful, forward it to someone in the cannabis space or hit the restack button on Substack. It’s how this community grows.